Detalles de la búsqueda
1.
Enhancing global access to cancer medicines.
CA Cancer J Clin
; 70(2): 105-124, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32068901
2.
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
N Engl J Med
; 386(6): 556-567, 2022 02 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35139274
3.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665782
4.
International multidisciplinary consensus on the integration of radiotherapy with new systemic treatments for breast cancer: European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Lancet Oncol
; 25(2): e73-e83, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38301705
5.
Integration of pathological criteria and immunohistochemical evaluation for invasive lobular carcinoma diagnosis: recommendations from the European Lobular Breast Cancer Consortium.
Mod Pathol
; : 100497, 2024 Apr 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38641322
6.
Radiotherapy statements of the 18th St. Gallen International Breast Cancer Consensus Conference-a German expert perspective.
Strahlenther Onkol
; 2024 Feb 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38393398
7.
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial.
Lancet Oncol
; 24(1): 77-90, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36493792
8.
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.
Oncologist
; 28(10): 856-865, 2023 10 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37523663
9.
Pembrolizumab for Early Triple-Negative Breast Cancer.
N Engl J Med
; 382(9): 810-821, 2020 02 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-32101663
10.
p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.
Mod Pathol
; 36(4): 100100, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36788081
11.
Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study.
Eur J Nucl Med Mol Imaging
; 50(8): 2477-2485, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36879065
12.
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy.
Int J Gynecol Cancer
; 33(5): 812-822, 2023 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36707086
13.
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol
; 23(5): 625-635, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405088
14.
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Breast Cancer Res
; 24(1): 58, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36056374
15.
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer.
Cancer
; 128 Suppl 11: 2209-2223, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35536015
16.
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
Br J Cancer
; 126(12): 1715-1724, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35194193
17.
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.
Oncologist
; 27(9): 722-731, 2022 09 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35704278
18.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31166679
19.
ERBB2 mutation is associated with sustained tumor cell proliferation after short-term preoperative endocrine therapy in early lobular breast cancer.
Mod Pathol
; 35(12): 1804-1811, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35842479
20.
Distress in hospitalized cancer patients: Associations with personality traits, clinical and psychosocial characteristics.
Psychooncology
; 31(5): 770-778, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-34894364